Stockreport

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease [Yahoo! Finance]

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com
PDF announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercialization of NILEMDO ® (bempedoic acid) and NEXLIZET ® ( [Read more]